Abstract
s / Biol Blood Marrow Transplant 21 (2015) S185eS205 S190 time to relapse from day 30 post-transplant was 69 days (range 41-230 days). The cumulative incidence of acute GVHD grade II-IV was 44% with 10% grade III-IV. The cumulative incidence of chronic GVHD at 2 years was 48%, with 22% extensive chronic GVHD. Conclusion: In this cohort of patients with AML/ MDS, MCP-1 levels at day 30 post allogeneic HCT in patients who had achieved complete remission and full chimerism were predictive of relapse two months on average prior to overt hematological relapse. Larger studies may find potential role of MCP-1 in predicting relapse post-transplant and development of early strategies for prevention.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
